Physician profile
David White
NPI 1871882357
$40,080.47
in general payments reported to CMS, 2019-2025
80 companies · $5,974 in 2025
The $5,974 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,333 · 2020: $5,181 · 2021: $4,519 · 2022: $3,670 · 2023: $5,947 · 2024: $6,456 · 2025: $5,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Consulting Fee: $2,138 · Education: $29.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,210.39 |
| Consulting Fee | $2,137.50 |
| Education | $29.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $11,429.26 | 2019-2025 | Ultomiris, Soliris |
| Ucb, INC. | $3,691.09 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Abbvie INC. | $2,755.62 | 2020-2025 | Botox, Ubrelvy, Qulipta |
| Argenx US, INC. | $1,988.71 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Pfizer INC. | $1,642.66 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,419.65 | 2019-2025 | |
| Amgen INC. | $969.72 | 2019-2025 | Uplizna, Aimovig |
| Genentech USA, INC. | $929.63 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Acadia Pharmaceuticals INC | $894.78 | 2019-2025 | Nuplazid |
| Acorda Therapeutics, INC | $820.79 | 2019-2023 | Inbrija |
| Neurocrine Biosciences, INC. | $785.99 | 2021-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $743.48 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Tanabe Pharma America, INC. | $700.01 | 2019-2025 | Radicava |
| Csl Behring | $683.55 | 2019-2024 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $554.17 | 2023-2025 | Rexulti, Nuedexta |
Show all 80 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.